Xeris Biopharma Holdings XERS Income Statement (2020-2026)

NASDAQ XERS
$8.34 -0.14 (-1.65%)
As of: Sep 9, 2026 · 12:53 PM EDT
Reported Financials

Xeris Biopharma Holdings Quarterly Income Statement

Periods 24 quarters
Latest Jun 2026

Xeris Biopharma Holdings reported revenue of $92.10M and net income of -$31.10M for the quarter ended Jun 2026, up 28.7% year over year. This income statement covers 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue
11.06M21.43M22.07M25.31M29.73M33.14M33.20M38.01M48.32M44.39M40.64M48.06M54.27M60.10M60.12M71.54M74.38M85.81M83.13M92.10M
Cost of RevenueCost of Rev
3.22M4.89M6.27M4.81M5.26M6.29M5.32M7.55M8.20M7.57M5.97M7.79M13.59M9.48M8.73M11.90M11.00M10.95M10.57M12.51M
Gross Profit
7.84M16.54M15.80M20.50M24.46M26.85M27.88M30.45M40.12M36.82M34.67M40.27M40.67M50.62M51.39M59.64M63.38M74.86M72.55M79.59M
Operating items
Amortization - Intangibles
0.55M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M
Research & DevelopmentR&D
5.66M10.08M6.25M3.72M6.04M4.96M4.84M6.09M5.03M6.38M7.82M5.76M5.89M6.09M7.75M8.05M7.48M7.87M8.78M10.67M
Selling, General & AdministrativeSG&A
26.54M54.18M35.91M32.98M34.49M34.36M33.60M37.63M37.29M37.57M38.38M39.99M44.97M40.14M44.02M44.39M46.46M47.50M53.14M61.03M
Other Operating ExpensesOther Opex
3.22M5.44M8.98M7.52M7.97M9.00M8.03M10.27M10.91M10.28M8.68M10.50M16.30M12.19M11.44M14.61M13.71M13.66M13.28M15.22M
Operating ExpensesOpex
35.42M69.70M51.15M44.22M48.51M48.31M46.47M53.99M53.23M54.23M54.88M56.25M67.16M58.42M63.21M67.06M67.65M69.03M75.21M86.93M
Operating IncomeOp. Inc
-24.36M-48.27M-29.07M-18.92M-18.78M-15.17M-13.28M-15.98M-4.91M-9.84M-14.24M-8.19M-12.89M1.68M-3.09M4.48M6.73M16.77M7.92M5.17M
EBIT
-24.36M-48.27M-29.07M-18.92M-18.78M-15.17M-13.28M-15.98M-4.91M-9.84M-14.24M-8.19M-12.89M1.68M-3.09M4.48M6.73M16.77M7.92M5.17M
Non-operating items
Non Operating Interest Expenses
1.80M1.80M3.52M3.45M4.00M4.37M6.22M6.53M6.85M7.01M7.03M8.00M7.80M7.70M7.30M7.40M7.30M7.17M6.90M6.95M
Interest & Investment IncomeInt & Inv Inc
0.07M0.07M0.07M0.20M0.47M1.84M1.30M1.22M1.12M1.11M1.92M1.29M1.20M0.91M1.18M0.95M1.16M1.46M1.20M1.46M
Other Non Operating IncomeOther Non Op Inc.
-1.65M-2.52M-5.05M-7.61M-3.39M1.90M-3.56M-4.54M-7.61M-2.80M-4.43M-6.07M-6.17M-6.79M-6.13M-6.41M-6.11M-5.69M-5.68M-36.27M
Net income details
EBT
-26.01M-50.79M-34.12M-26.52M-22.17M-13.27M-16.83M-20.52M-12.53M-13.63M-18.67M-14.26M-19.06M-5.11M-9.22M-1.93M0.62M11.08M2.23M-31.10M
Tax ProvisionsTaxes
-0.41M-0.34M-0.34M-0.34M-0.68M-0.34M-0.24M0.31M0.75M-3.32M
Profit After TaxPAT
-26.02M-50.80M-33.71M-26.18M-21.83M-12.92M-16.83M-19.84M-12.19M-13.37M-18.98M-15.01M-15.74M-5.11M-9.22M-1.93M0.62M11.08M2.23M-31.10M
Income from Continuing OperationsIncome (Continuing)
-26.01M-50.79M-33.71M-26.18M-21.83M-12.93M-16.83M-19.84M-12.19M-13.39M-18.98M-15.01M-15.74M-5.11M-9.22M-1.93M0.62M11.08M2.23M-31.10M
Consolidated Net IncomeConsol Net Inc.
-26.01M-50.79M-33.71M-26.18M-21.83M-12.93M-16.83M-19.84M-12.19M-13.39M-18.98M-15.01M-15.74M-5.11M-9.22M-1.93M0.62M11.08M2.23M-31.10M
Income towards Parent CompanyParent Net Inc
-26.01M-50.79M-33.71M-26.18M-21.83M-12.93M-16.83M-19.84M-12.19M-13.39M-18.98M-15.01M-15.74M-5.11M-9.22M-1.93M0.62M11.08M2.23M-31.10M
Net Income towards Common StockholdersNet Income
-26.01M-50.79M-33.71M-26.18M-21.83M-12.93M-16.83M-19.84M-12.19M-13.39M-18.98M-15.01M-15.74M-5.11M-9.22M-1.93M0.62M11.08M2.23M-31.10M
Additional items
EPS (Basic)
-0.39-0.64-0.25-0.19-0.16-0.10-0.12-0.14-0.09-0.10-0.14-0.10-0.11-0.03-0.06-0.010.000.070.01-0.18
EPS (Diluted)
-0.39-0.64-0.25-0.19-0.16-0.10-0.12-0.14-0.09-0.10-0.14-0.10-0.11-0.03-0.06-0.010.000.060.01-0.18
Shares Outstanding
66.50M79.03M135.03M135.53M135.95M135.63M137.14M137.34M138.06M137.67M140.51M148.35M148.99M146.77M152.45M159.46M163.65M160.43M170.52M172.82M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
66.50M79.03M135.03M135.53M135.95M135.63M137.14M137.34M138.06M137.67M140.51M148.35M148.99M146.77M152.45M159.46M177.62M172.74M177.63M172.82M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
66.50M79.03M135.53M135.96M135.96M136.27M137.29M138.01M138.07M138.13M148.22M148.94M149.00M149.43M156.01M161.22M165.53M166.22M172.56M173.59M
EBITDA
-24.36M-48.27M-29.07M-18.92M-18.78M-15.17M-13.28M-15.98M-4.91M-9.84M-14.24M-8.19M-12.89M1.68M-3.09M4.48M6.73M16.77M7.92M5.17M
Interest ExpensesInt Expense
1.80M1.80M3.52M3.45M4.00M4.37M6.22M6.53M6.85M7.01M7.03M8.00M7.80M7.70M7.30M7.40M7.30M7.17M6.90M6.95M
Tax Rate
1.20%1.28%1.53%2.55%3.29%2.70%1.73%-1.64%-5.25%17.44%